Literature DB >> 11689672

Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen.

T Matano1, M Kano, H Nakamura, A Takeda, Y Nagai.   

Abstract

Heterologous prime/boost regimens are AIDS vaccine candidates because of their potential for inducing cellular immune responses. Here, we have developed a prime/boost regimen leading to rapid control of highly pathogenic immunodeficiency virus infection in macaques. The strategy, priming by an env and nef deletion-containing simian-human immunodeficiency virus (SHIV) proviral DNA followed by a single booster with a Gag-expressing Sendai virus (SeV-Gag), efficiently induced virus-specific T cells, which were maintained for more than 3 months until challenge. While all naive control macaques showed acute CD4(+) T-cell depletion at week 2 after an intravenous SHIV89.6PD challenge, all the macaques vaccinated with the prime/boost regimen were protected from depletion and showed greatly reduced peak viral loads compared with controls. Vaccination with the DNA alone or SeV-Gag alone was not enough to confer the consistent protection from the depletion, although it led to efficient secondary CD8(+) T-cell responses at week 2 after challenge. At week 1, a difference in the secondary responses between the protected and the unprotected macaques was clear; rapid augmentation of virus-specific CD8(+) T cells was detected in the former but not in the latter. Thus, our results indicate the importance of rapid secondary responses for reduction in the peak viral loads and protection from acute CD4(+) T-cell depletion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689672      PMCID: PMC114777          DOI: 10.1128/JVI.75.23.11891-11896.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

Review 1.  AIDS vaccine development in primate models.

Authors:  N M Almond; J L Heeney
Journal:  AIDS       Date:  1998       Impact factor: 4.177

2.  Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques.

Authors:  T Matano; R Shibata; C Siemon; M Connors; H C Lane; M A Martin
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

3.  Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense.

Authors:  A Kato; Y Sakai; T Shioda; T Kondo; M Nakanishi; Y Nagai
Journal:  Genes Cells       Date:  1996-06       Impact factor: 1.891

4.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.

Authors:  J E Schmitz; M J Kuroda; S Santra; V G Sasseville; M A Simon; M A Lifton; P Racz; K Tenner-Racz; M Dalesandro; B J Scallon; J Ghrayeb; M A Forman; D C Montefiori; E P Rieber; N L Letvin; K A Reimann
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

5.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

Authors:  E S Rosenberg; J M Billingsley; A M Caliendo; S L Boswell; P E Sax; S A Kalams; B D Walker
Journal:  Science       Date:  1997-11-21       Impact factor: 47.728

6.  Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS.

Authors:  Y Lu; C D Pauza; X Lu; D C Montefiori; C J Miller
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-09-01

7.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P R Dunbar; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; V Cerundolo; A Hurley; M Markowitz; D D Ho; D F Nixon; A J McMichael
Journal:  Science       Date:  1998-03-27       Impact factor: 47.728

8.  CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection.

Authors:  M Matloubian; R J Concepcion; R Ahmed
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  Rapid effector function in CD8+ memory T cells.

Authors:  A Lalvani; R Brookes; S Hambleton; W J Britton; A V Hill; A J McMichael
Journal:  J Exp Med       Date:  1997-09-15       Impact factor: 14.307

View more
  32 in total

1.  Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles.

Authors:  Gillis Otten; Mary Schaefer; Catherine Greer; Maria Calderon-Cacia; Doris Coit; Jina Kazzaz; Angelica Medina-Selby; Mark Selby; Manmohan Singh; Mildred Ugozzoli; Jan zur Megede; Susan W Barnett; Derek O'Hagan; John Donnelly; Jeffrey Ulmer
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

2.  Impact of vaccination on cytotoxic T lymphocyte immunodominance and cooperation against simian immunodeficiency virus replication in rhesus macaques.

Authors:  Hiroshi Ishii; Miki Kawada; Tetsuo Tsukamoto; Hiroyuki Yamamoto; Saori Matsuoka; Teiichiro Shiino; Akiko Takeda; Makoto Inoue; Akihiro Iida; Hiroto Hara; Tsugumine Shu; Mamoru Hasegawa; Taeko K Naruse; Akinori Kimura; Masafumi Takiguchi; Tetsuro Matano
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

3.  Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens.

Authors:  Lan Wu; Wing-Pui Kong; Gary J Nabel
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques.

Authors:  Miki Kawada; Hiroko Igarashi; Akiko Takeda; Tetsuo Tsukamoto; Hiroyuki Yamamoto; Sachi Dohki; Masafumi Takiguchi; Tetsuro Matano
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine.

Authors:  Miki Kawada; Tetsuo Tsukamoto; Hiroyuki Yamamoto; Akiko Takeda; Hiroko Igarashi; David I Watkins; Tetsuro Matano
Journal:  J Virol       Date:  2007-03-07       Impact factor: 5.103

6.  Control of simian immunodeficiency virus replication by vaccine-induced Gag- and Vif-specific CD8+ T cells.

Authors:  Nami Iwamoto; Naofumi Takahashi; Sayuri Seki; Takushi Nomura; Hiroyuki Yamamoto; Makoto Inoue; Tsugumine Shu; Taeko K Naruse; Akinori Kimura; Tetsuro Matano
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

7.  Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.

Authors:  John R Mascola; Mark G Lewis; Thomas C VanCott; Gabriela Stiegler; Hermann Katinger; Michael Seaman; Kristin Beaudry; Dan H Barouch; Birgit Korioth-Schmitz; Georgia Krivulka; Anna Sambor; Brent Welcher; Daniel C Douek; David C Montefiori; John W Shiver; Pascal Poignard; Dennis R Burton; Norman L Letvin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Reversion in vivo after inoculation of a molecular proviral DNA clone of simian immunodeficiency virus with a cytotoxic-T-lymphocyte escape mutation.

Authors:  Masahiro Kobayashi; Hiroko Igarashi; Akiko Takeda; Moriaki Kato; Tetsuro Matano
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.

Authors:  N A Doria-Rose; C Ohlen; P Polacino; C C Pierce; M T Hensel; L Kuller; T Mulvania; D Anderson; P D Greenberg; S-L Hu; N L Haigwood
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.